Breaking News

Financial Report: AbbVie

October 25, 2013

Humira sales up 19% in the quarter


3Q Revenues: $4.7 billion (+3%)

3Q Earnings: $964 million (-39%)

YTD Revenues: $13.7 billion (+4%)

YTD Earnings: $3.0 billion (-20%)

Comments: Humira sales were $2.8 billion in the quarter, up 19%. AndroGel and Kaletra sales were down 11% to $248 million and $237 million, respectively. Niaspan sales were down 13% to $201 million. TriCor/Trilipix sales were down 88% to $39 million, due to loss of exclusivity. Synthroid sales were up 23% to $161 million. Creon and Zemplar sales were up 10% to $101 million and $100 million, respectively. R&D expenses were down 12% to $714 million.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks